Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Vestibular SchwannomaNeurofibromatosis Type 2

Interventions

DRUG

Endostatin

Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.

Trial Locations (1)

Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors

collaborator

Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

INDUSTRY

lead

Beijing Tiantan Hospital

OTHER

NCT02104323 - Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Biotech Hunter | Biotech Hunter